Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran Seeking Alpha, 13 Oct 2023 Summary We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for…